NCT01147484 - A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2010

Primary Completion Date

December 14, 2014

Study Completion Date

February 13, 2015

Conditions

Recurrent Breast Cancer

Interventions

DRUG

Foretinib

foretinib, at a continuous oral daily dose of 60 mg

Trial Locations (9)

Tom Baker Cancer Centre, Calgary

BCCA - Cancer Centre for the Southern Interior, Kelowna

BCCA - Vancouver Cancer Centre, Vancouver

QEII Health Sciences Centre, Halifax

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

London Regional Cancer Program, London

Ottawa Health Research Institute - General Division, Ottawa

Hopital Charles LeMoyne, Greenfield Park

Allan Blair Cancer Centre, Regina